Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Trading Down 4.6 %

Shares of NASDAQ APTO opened at $0.23 on Tuesday. The stock has a market capitalization of $13.56 million, a PE ratio of -0.08 and a beta of 1.07. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.60. The stock has a fifty day simple moving average of $0.28 and a 200-day simple moving average of $0.43.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.